« フランキンセンスCO2-se5mlの精油成分酢酸インセンスオールについて | Main | リウマチ関節炎対策(アロマセラピー・食事) »

April 09, 2018


Copaiba: Silver bullet or snake oil?

コパイバ精油は特効薬または偽薬? Science daily より

Silver bullet 特効薬

Sales of the essential oil copaiba [koh-pey-buh] are increasing, at least in part, because more than 54 million Americans suffer from some form of arthritis and 23.7 million are limited in their usual activity primarily due to pain. The conventional way to treat arthritis is using nonsteroidal, anti-inflammatory drugs (NSAIDs) as well as cyclo-oxygenase-2 inhibitors (COXIBs), which are not without adverse events like gastrointestinal bleeding, heart attacks and stroke. For arthritis sufferers, copaiba may turn out to be a silver bullet or, perhaps, snake oil.


nonsteroidal, anti-inflammatory drugs (NSAIDs) 非ステロイド性抗炎症薬(NSAID
cyclo-oxygenase-2 inhibitors (COXIBs) シクロオキシナーゼ-2阻害薬
adverse events 有害事象
gastrointestinal bleeding 消化管出血

The side effects of NSAIDs and COXIBs as well as warnings from the U.S. Food and Drug Administration on their risks of gastrointestinal side effects and bleeding as well as cardiovascular disease all suggest the need to test novel therapies with potential clinical benefits and fewer side effects than the available traditional medicines. One such possible remedy is Copaifera reticulate or copaiba.

非ステロイド性抗炎症薬(NSAID)およびシクロオキシナーゼ-2阻害薬の副作用ならびに消化管副作用および出血ならびに心血管疾患のそれらのリスクに関する米国食品医薬局(FDA)の警告のいずれも利用可能な伝統医薬より潜在的に臨床的有用性および副作用の少ない新規な療法を試験する必要性を示唆している。そのような可能性のある療法はCopaifera reticulate またはコパイバです。

The U.S. Food and Drug Administration  米国食品医薬局(FDA)
gastrointestinal side effects 消化管副作用
clinical benefits 臨床的有用性
traditional medicines 伝統医薬

The totality of evidence concerning the potential of copaiba to treat inflammatory arthritis is limited to basic research and uncontrolled clinical observations in humans.Researchers from Florida Atlantic University caution that randomized trials are necessary to discern whether the treatment is effective or that copaiba turns out to be "yet another beautiful hypothesis slain by ugly facts." They present the incomplete totality of evidence and challenges in treating arthritis in their commentary published in the journal Integrative Medicine.


ugly facts 醜い事実
Florida Atlantic University フロリダ・アトランティック大学
randomized controlled trial 無作為化試験

"Copaiba is an essential oil that is used topically with little or no side effects, but there is insufficient evidence to judge whether it reduces pain and inflammation in patients with arthritis," said Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll Professor, senior academic advisor to the dean in FAU's Charles E. Schmidt College of Medicine, and senior author of the paper."In case reports, individuals with joint pain and inflammation who used copaiba reported favorable results, however, this hypothesis is promising but as of yet unproven."

「コパイバは少量を局所的に使用され、ほとんど副作用のない精油ですが、関節炎患者の痛みや炎症を軽減するかどうかを判断するにはエビデンスが不十分であると、Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll Professor, senior academic advisor to the dean in FAU's Charles E. Schmidt College of Medicine, and senior author of the paper.は述べた。症例報告では、コパイバ精油を使用している関節痛や炎症のある人には好意的な結果が報告されたが、この仮説は有望であるが、まだ証明されていない。

Copaiba is a stimulant oleoresin obtained from the trunk of several pinnate-leaved South American leguminous trees found in the Amazon. Its medicinal usage dates back to the 16th century when natives of Brazil used it as folk medicine. Today, Brazil produces approximately 95 percent of this oil-resin, exporting more than 500 tons each year.


pinnate 羽状の

"Basic research has suggested mechanisms of benefit of this essential oil in treating inflammatory arthritis," said Hennekens. "Nonetheless, the only published data on copaiba on humans includes one case series and one small randomized trial of another inflammatory condition and not arthritis."


In the commentary, the researchers conclude that the totality of the currently available evidence for copaiba essential oil is wholly insufficient to judge either its benefits or risks for the relief of pain and inflammation in arthritis. They emphasize that despite the absence of reliable evidence from large-scale randomized clinical trials, sales of copaiba continue to increase, presenting clinical and public health challenges.


"To complete the totality of evidence, copaiba should be first tested in a randomized trial against a placebo in patients with inflammatory arthritis," said Hennekens. "If such a trial shows a net benefit, then the next step would be direct randomized comparisons against NSAIDs and COXIBs."

「根拠の全体性を完成させえるために、炎症性関節炎患者のプラセボに対する無作為試験で、コパイバを最初に試験すべきである」とHennekens.は述べた。「このような試験が正味の利益をしめしたなら、次のステップは非ステロイド性抗炎症薬(NSAID)およびシクロオキシナーゼ-2阻害薬(COXIBs) との無作為比較を直接行うことだろう」


コパイバ バルサム5ml・精油






« フランキンセンスCO2-se5mlの精油成分酢酸インセンスオールについて | Main | リウマチ関節炎対策(アロマセラピー・食事) »